华安证券给予众生药业买入评级：创新药产品布局丰富，甲流产品蓄势待发

Group 1 - The core viewpoint of the report is that Zhongsheng Pharmaceutical (002317.SZ) is rated as a "buy" due to its solid foundation in traditional Chinese medicine and stable development of its proprietary Chinese medicine business [2] - The company is expected to benefit from the market potential of its innovative drug, Anladiwei tablets, for treating influenza [2] - The ongoing research product, RAY1225 injection, a long-acting GLP-1 class drug, has shown promising data, and there is a focus on overseas rights authorization [2]